Leptin is expressed in the placenta and in certain fetal tissues ; however, little is known with regard to the function of this hormone in these tissues. T o date, most evidence suggests that placental and/or fetal leptin acts as a fetal growth factor, but this is far from clear. Leptin may also have physiological effects on the placenta, including angiogenesis, growth and immunomodulation. T h e effects of placental leptin, if any, on the mother may contribute to endocrine-mediated alterations in energy balance, such as the mobilization of maternal fat, which occurs during the second half of pregnancy. In this review we will address these and other issues related to the expression of both placental and fetal leptin.
Introduction
Leptin (also known as OB), the protein product of the ob gene, is a 16 kDa hormone whose principal site of synthesis and secretion is white adipose tissue, although expression of leptin now appears to be much more widespread than originally thought; the stomach, muscle, placenta and fetal tissues have all been shown to express leptin (for a review, see [l] ). Leptin is considered to be 'a signalling molecule to the brain which is involved in the regulation of whole-body energy balance. However, it is increasingly recognized that leptin has a number of other functions [l].
Reproduction is one such area where a role for leptin has been established (for reviews, see [2, 3] ). Administration of leptin can restore the fertility of genetically leptin-deficient ob/ob mice [4], and can accelerate the onset of puberty in normal female rodents [5,6]. Moreover, leptin levels rise in the maternal circulation towards the end of pregnancy in humans and rodents, with a fall in titre to below pre-pregnancy levels at around birth. In the mouse, serum leptin increases 25-fold [7] in the maternal circulation, compared with a 3-fold rise in humans [8] and rats [9] . Although human maternal fat deposition increases during pregKey words: leptin receptor, placenta, pregnancy. 'To whom correspondence should be addressed (e-mail nh@m.sari.ac.uk).
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nancy, this does not appear to correlate with the changes in circulating leptin [lo] . However, it should be noted that, in one study carried out on age-matched rats, maternal leptin levels remain unchanged until day 20 of pregnancy, after which they decreased [ 1 11.
Placental expression
One possible explanation for the increase in circulating levels of leptin towards the end of pregnancy is synthesis by the placenta. Both the human [ 10,121 and murine [ 131 placenta have been shown to express both leptin and the leptin receptor.
T h e leptin receptor (OB-R) gene has at least several splice variants (OB-Ra-OB-Rf), a number of which have been identified in the murine placenta. These include OB-Rb, the signalling form of the leptin receptor, OB-Ra, the proposed transport form of the receptor [13] , and OB-Re, the soluble form of the receptor [14].
T h e human placenta shows substantial expression of leptin mRNA and protein [lo].
Comparable amounts of immunoreactive leptin protein are present in the rodent placenta (see Figure 2) , although the expression of rodent placental leptin mRNA appears much lower than in humans [7, 11, 15] . T h e significance of this species difference in the expression of placental leptin remains to be determined, but clearly has implications when studying the function of placental leptin across species. It is unlikely that the leptin expressed in the rodent placenta contributes significantly to the fetal or maternal circulating levels of leptin. The relatively high level of leptin protein in the murine placenta probably reflects, to a large extent, binding of leptin to its receptor. The significance of the placenta as a target for leptin is unknown.
Human leptin mRNA and protein are colocalized to the syncytiotrophoblast, which is in direct contact with maternal blood, and to the villous vascular endothelial cells, in direct contact with the fetal blood (Figure 1) [16] . T Human placental leptin is identical to that of adipose origin on the basis of size, charge and immunoreactivity [17] . However, although it has the same promoter, the human placental leptin gene has a placenta-specific upstream enhancer [18] . This suggests that the expression of the leptin gene in the placenta is regulated differently from that in adipose tissue. By implication, placental leptin may play a distinct role during pregnancy. It is yet to be established if a placental leptin enhancer exists in species other than humans.
Human placental leptin levels are affected by a number of factors, including forskolin, retinoids and PMA [19, 20] . Interestingly, forskolin stimulates the expression of leptin in the placenta, but inhibits it in adipose tissue. Maternal hormones that affect adipose leptin production, and which change during pregnancy, may also regulate placental leptin production [21]. For example, Hardie et al.
[8] described a positive correlation between maternal circulating leptin and oestradiol concentrations.
Function of placentally derived leptin in the mother
T h e function of placentally derived leptin in the mother is not clear; however, it may have endo- 
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Function of placental/fetal leptin in the fetus
There is no correlation between maternal leptin levels and fetal weight ; however, several studies have reported that umbilical cord blood leptin levels are positively correlated with fetal insulin, birth weight, ponderal index (kg/cm3), length and head circumference [31-331. This suggests a potential role for leptin in fetal growth. T h e higher leptin levels in umbilical veins compared with umbilical arteries, and the marked fall during the neonatal period, indicate that the human placenta is one of the major sources of leptin in the fetal circulation [34] (Figure 2) . In support of this, leptin is secreted at significant levels from the perfused ex vivo term human placenta into both the maternal (median 201 ; interquartile range 101-376 ng/min per placenta) and fetal (median 89; interquartile range 51-112 ng/min per placenta) circulations, with a greater rate of secretion into the maternal circulation [35]. This is in addition to any contribution that fetal tissues, such as adipose tissue, heart and liver, might make to the circulating levels of fetal leptin [15,36]. In studies using the perfused human placenta to measure placental leptin production in isolation, we have described a significant relationship between the ratio of fetal to placental weight and the placental export of leptin into the maternal, but not the fetal, circulation [35]. This finding suggests that maternal placental leptin may be produced in response to the rate of fetal growth relative to the placental delivery of nutrients, rather than the absolute rate of fetal growth. Fat represents over half the caloric accretion of the fetus in the last trimester of pregnancy. Therefore one possible function of the leptin exported into the maternal circulation at this stage of pregnancy may be to increase the mobilization of maternal fat stores in order to support fetal growth in response to the discrepancy between fetal demand and placental supply.
Our studies and others have shown that both placental and cord blood leptin levels are decreased in pregnancies complicated by fetal growth retardation, and increased in those complicated by maternal diabetes [16,28,37-391. In a 33-week twin pregnancy where one twin was growth retarded and the other of normal size, both placental and cord blood leptin levels were lower in association with the growth-retarded fetus [16] (Figure 1 ).
Type I (insulin-dependent) diabetes mellitus during pregnancy is frequently associated with large-for-gestational-age infants (macrosomia). This is thought to be a consequence of the stimulatory effects of maternal hyperglycaemia on the fetal pancreas, which result in fetal hyperinsulinaemia [40]. We have also found, along with other groups, that elevated cord blood insulin is associated with elevated levels of cord blood and placental leptin [16, 28] . A role for leptin in stimulating pancreatic development has been o Mobilization of energy stores suggested [41], which could result in early insulin production and stimulate an increase in fetal growth. Alternatively, fetal hyperinsulinaemia could stimulate increased fetal and placental leptin production, which could in turn contribute to increased fetal growth in tissues expressing the leptin receptor.
Further evidence for leptin targeting in the fetus comes from our studies showing that leptin receptor mRNA is expressed by specific tissues in the mouse fetus However, it should be noted that, in studies on the leptin-deficient oblob mouse, although leptin administration prior to conception was shown to be essential for a successful pregnancy 
Conclusions
Of the various possibilities, most evidence to date indicates that leptin (placental and/or fetal) may act as a fetal growth factor. Leptin may also have physiological effects on the placenta, including angiogenesis, growth and immunomodulation.
T h e effects of placental leptin, if any, on the mother are less clear, but it may contribute to endocrine-mediated alterations in energy balance, such as the mobilization of maternal fat that occurs during the second half of pregnancy. Changes in leptin activity in the fetus and at the maternal-fetal interface, and the functions of placental leptin, are clearly important areas for future research (Figure 3 ).
We are grateful to Leif Hunter, Lisa Hannah and Sarah Allstaff for skilled assistance. The work conducted in the authors' laboratories was funded by the Scottish Executive Rural Affairs Department. This is a contribution from ACERO (Aberdeen Centre for Energy Regulation and Obesity). cytokine receptors, which are single-pass transmembrane chains containing sequences of highly conserved amino acids in both the extracellular and the intracellular domains; members of this family share several structural and functional characteristics [l] . Members of this superfamily of receptors include receptors for granulocyte colony-stimulating factor, granulocyte/macrophage colony-stimulating factor, erythropoietin, thrombopoietin, several of the interleukins, prolactin (PRL), growth hormone (GH) and leptin [1, 2] . These receptors mediate a myriad of endocrine, paracrine and autocrine events, and their stimulation has been implicated in a range of developmental processes. These include the successful implantation of the fertilized ovum in a receptive uterus, the differentiation and development of embryonic organs and tissues, and the successful transition of the fetus to extra-uterine life [2, 3] . As the mechanisms underlying receptor activation and intracellular signalling have been elucidated, and as target genes have been characterized in specific tissues, new light has been thrown on the potential role of the ligands for these receptors in development. While it has been well established that the fetal pituitary gland in many species secretes PRL and G H , the physiological roles and/or target sites of action for these hormones in fetal life have remained unclear. T h e elucidation of the tissuespecific profile of expression of PRL receptors (PRLRs) and G H receptors (GHRs) during embryonic and fetal development has provided a new impetus for the delineation of the specific roles of PRL and GH in development [3]. This review aims to integrate current information on the
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